APR 07, 2016 12:00 PM PDT

MRSA Screening Program at a Community Healthcare System

C.E. CREDITS: P.A.C.E. CE
Speakers
  • Clinical Scientist in Microbiology, Immunology, and Molecular, Pathology Consultants of South Broward, LLP, Memorial Healthcare System
    Biography
      Rodney Arcenas earned a B.S. with Honors in Microbiology from the University of Florida in the spring of 1997. He continued his Microbiology training at the University Of South Florida College Of Medicine graduating in 2002 with a M.S. and Ph.D. in Medical Microbiology and Immunology. Dr. Arcenas was then accepted into the Clinical Microbiology Fellowship program at the Mayo Clinic in Rochester, MN. After completing his fellowship, he was hired in 2004 at LabOne, Inc. in Lenexa, Kansas to be their Scientific Director of Microbiology and Immunology. He left LabOne, Inc. in 2006 to join the Pathology Consultants of South Broward (PCSB) as their Clinical Scientist for Microbiology/Molecular Testing and has been there since. In his time with PCSB, Dr. Arcenas has helped to start the Molecular Infectious Disease testing service that has grown from a day-shift (8-hr, Mon - Fri) operation with 2 Medical Technologists to having 5 full time and 3 part time Medical Technologists with 24-hr shifts (Mon - Fri) and an abbreviated 1.5 shifts on the weekends. He also has helped spearhead the implementation of a successful MRSA active surveillance program that started in 2008. Dr. Arcenas is board certified as a Diplomate of the American Board of Medical Microbiology.

    Abstract:

    Healthcare-associated infections (HAIs) continue to be a considerable problem for hospitals and healthcare institutions that can adversely affect patient outcomes and impact the financial bottom lines. There are a number of strategies hospitals may implement for combating and controlling HAIs. Methicillin Resistant Staphylococcus aureus (MRSA) is one of those HAIs that can cause significant morbidity and mortality. Minimizing or eliminating the potential for infection is one main driver for a hospital to consider and develop a screening/surveillance program. Other factors include pressures from states passing legislation requiring a MRSA program to be implemented and CMS’s initiatives to prevent HAIs in general. The scope and clinical utility of a MRSA screening or active surveillance program is institution dependent and an assessment of the MRSA prevalence will help drive the decision to implement a formal Infection Control program. The identification of MRSA colonized patients is critical in directing Infection Control efforts towards limiting the risk of infection, and decreasing the likelihood that MRSA colonized patients become reservoirs of infection that could potentially be transmitted to other patients via the healthcare worker. In this presentation, we describe our successes and other lessons learned during our experiences in developing and implementing an active surveillance MRSA program in a large community healthcare system.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    Loading Comments...